While pharmacologic therapies remain central to managing PsO and PsA, non-pharmacologic interventions also play a crucial ...
Delays in diagnosing and treating psoriatic arthritis—a common inflammatory disorder affecting around 200,000 people in the U ...
The findings highlight the potential benefits of newer biologics targeting IL-12, IL-23, and IL-17 while also raising ...
A new study explores gaps in how patients and physicians view psoriatic arthritis (PsA) and recommends ways for clinicians to ...